UCB’s General Meeting of Shareholders 2026

Brussels (Belgium), 30 April 2026 – 18:00 (CEST) (regulated information) – Today, UCB held its Annual General Meeting of Shareholders (AGM). The ordinary and special meeting was followed by an extraordinary shareholders’ meeting. The Company offered the choice to UCB shareholders to either participate in-person or to cast their vote by proxy. At the AGM, 161,825,557 shares (84,89% of the shares entitled to vote) were present or represented. 

The message of Mr. Jean-Christophe Tellier, Chief Executive Officer of UCB, published at the occasion of this general meeting, is available on the UCB website.

During his speech, UCB’s CEO Jean-Christophe Tellier commented: “2025 has been a year of strong performance and meaningful progress. But more importantly, it has been a year where we have continued to build momentum in our business, in our pipeline and in our impact for patients. And this is what gives us confidence for the future.”

The AGM approved for the financial year 2025 the payment of a gross dividend of € 1.45 per share (€ 1.015 net per share after deduction of a Belgian withholding tax of 30%), via our paying agent, KBC Bank NV. This compares to a gross dividend of € 1.39 per share for 2024 (net dividend of € 0.973 per share). The ex-dividend date is 4 May 2026, the dividend will be payable as of 6 May 2026 (coupon no. 29).

During the AGM, the mandates of Jean-Christophe Tellier alongside that of Cédric van Rijckevorsel were renewed in their capacity as directors for a term of 4 years.

The AGM also acknowledged the departure of Professor Dame Kay Davies. During their speeches, Jean-Christophe Tellier, CEO and Jonathan Peacock, Chair of the Board, expressed their deepest gratitude in the name of UCB and themselves to Professor Dame Kay Davies for her invaluable contributions to UCB’s Board as Chair of the Governance, Nomination and Compensation Committee, as well as member of the Scientific Committee.

They also thanked Rodolfo Savizky who has stepped down from the Board with effect as of end of the day today.

In replacement of Rodolfo, the Board of directors also announced during the meeting that it has co-opted Judy Brown as a new member. Judy will officially join the Board on May 1, 2026 and will become the Chair of the Audit Committee. Her mandate will be submitted for confirmation to the Annual General Meeting in 2027. Judy has extensive experience as CFO in the Health Care sector and as Board member in US listed companies. The Board of directors, as well as each of its special committees, continues to be composed of a majority of independent directors. The Board composition will also continue to be compliant with the requirement of the BCCA (Belgian Code of Companies and Associations) that at least one third of the members of the Board must be of a different gender than that of the other members.

For the curriculum vitae of the Board members, please visit the UCB website: https://www.ucb.com/investors/UCB-governance. 

All other agenda items put to vote at the AGM were approved by the shareholders. More information including details of the votes will be available soon on UCB's website.

The Integrated Annual Report 2025 of UCB can be downloaded on UCB's website at https://www.ucb.com/investors/Download-center or is available on the online portal at https://reports.ucb.com/.

The financial results for the first half year 2026 will be published on 30 July 2026. 

Next year's General Meeting will be held on 29 April 2027.

For further information, contact UCB:

Investor Relations
Antje Witte
T +32.2.559.9414
Antje.witte@ucb.com 

Yvonne Naughton
T: +44-7566790245
yvonne.naughton@ucb.com

Sahar Yazdian 
T: +32.2.559.9137 
mailto:sahar.yazdian@ucb.com

Global Communications 
Laurent Schots
T+32.2.559.9264
Laurent.schots@ucb.com 

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 9,000 people in approximately 40 countries, the company generated revenue of €7.7 billion in 2025. UCB is listed on Euronext Brussels (symbol: UCB).

Forward looking statement
This document contains forward-looking statements, including, without limitation, statements containing the words “potential”, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guaranteeing future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this document. 
Important factors that could result in such differences include but are not limited to: global spread and impacts of wars and pandemics, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring and retention of its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB’s efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB’s products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB’s data and systems.
Given these uncertainties, you are cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this document, and do not reflect any potential impacts from the evolving conflicts, wars, pandemics, as well as any other adversity, unless indicated otherwise. The company continues to follow the development diligently to assess the financial significance of these events, as the case may be, to UCB.
UCB expressly disclaims any obligation or duty to update any forward-looking statements in this document, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.